Factor XII: A drug target for safe interference with thrombosis and inflammation

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1459-1464

  Kenne, Ellinor ^a,b   Renné, Thomas ^a,b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; ANTIBODY; ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULATION; DRUG MECHANISM; DRUG TARGETING; EXTRACORPOREAL OXYGENATION; HUMAN; IN VIVO STUDY; INFLAMMATION; NONHUMAN; REVIEW; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR XII; FACTOR XIIA; HEMORRHAGE; HEPARIN; HUMANS; INFLAMMATION; THROMBOSIS;

EID: 84907812263     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.024     Document Type: Review

References (88)

1. H.K. de Jong The systemic pro-inflammatory response in sepsis J. Innate Immun. 2 2010 422 430
2. M. O'Brien The reciprocal relationship between inflammation and coagulation Topics Comp. Anim. Med. 27 2012 46 52
3. J. Petaja Inflammation and coagulation. An overview Thrombosis Res. 127 Suppl. 2 2011 S34 S37
4. J. Back Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus Arthritis Res. Ther. 15 2013 R206
5. T. van der Poll Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees J. Exp. Med. 179 1994 1253 1259
6. C.T. Esmon Crosstalk between inflammation and thrombosis Maturitas 47 2004 305 314
7. W.B. Kannel Overview of hemostatic factors involved in atherosclerotic cardiovascular disease Lipids 40 2005 1215 1220
8. K.E. Welty-Wolf Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons Am.J. Respir. Crit. Care Med. 164 2001 1988 1996
9. M.S. Carraway Blockade of tissue factor: treatment for organ injury in established sepsis Am. J. Respir. Crit. Care Med. 167 2003 1200 1209
10. H. Herwald Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4 J. Biol. Chem. 271 1996 13061 13067
11. T. Renne Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2 J. Biol. Chem. 274 1999 25777 25784
12. T. Renne In vivo roles of factor XII Blood 120 2012 4296 4303
13. D.E. Cool, and R.T. MacGillivray Characterization of the human blood coagulation factor XII gene Intron/exon gene organization and analysis of the 5′-flanking region J. Biol. Chem. 262 1987 13662 13673
14. J.J. Veltkamp The biological half-time of Hageman factor Thromb. Diath. Haemor. 13 1965 1 7
15. D.E. Cool Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa J. Biol. Chem. 260 1985 13666 13676
16. S.D. Revak Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma J. Exp. Med. 147 1978 719 729
17. J. Bjorkqvist Plasma kallikrein: the bradykinin-producing enzyme Thromb. Haemost. 110 2013 399 407
18. T. Renne Local bradykinin formation is controlled by glycosaminoglycans J. Immunol. 175 2005 3377 3385
19. M. Cicardi Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema N. Engl. J. Med. 363 2010 532 541
20. J. Bjorkqvist Hereditary angioedema: a bradykinin-mediated swelling disorder Thromb. Haemost. 109 2013 368 374
21. C. Oschatz Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo Immunity 34 2011 258 268
22. G. Dewald, and K. Bork Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor Biochem. Biophys. Res. Commun. 343 2006 1286 1289
23. S. Cichon Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III Am. J. Hum. Genet. 79 2006 1098 1104
24. K. Bork Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys Blood Coagul. Fibrinolysis 20 2009 325 332
25. O.D. Ratnoff, and J.E. Colopy A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma J. Clin. Invest. 34 1955 602 613
26. R. Kumar, and M. Carcao Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond Pediatr. Clin. N. Am. 60 2013 1419 1441
27. W.M. Halbmayer The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism Thromb. Haemost. 68 1992 285 290
28. G. Lessiani Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis J. Thromb. Thrombolysis 27 2009 348 351
29. J. Bach Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk J. Thromb. Haemost. 6 2008 291 296
30. A. Girolami The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature J. Thromb. Thrombolysis 17 2004 139 143
31. S. Zeerleder Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency: a study on 73 subjects from 14 Swiss families Thromb. Haemost. 82 1999 1240 1246
32. T. Koster John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study Br. J. Haematol. 87 1994 422 424
33. H.U. Pauer Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo Thromb. Haemost. 92 2004 503 508
34. T. Renne Defective thrombus formation in mice lacking coagulation factor XII J. Exp. Med. 202 2005 271 281
35. C. Kleinschnitz Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis J. Exp. Med. 203 2006 513 518
36. F. Muller Factor XI and XII as antithrombotic targets Curr. Opin. Hematol. 18 2011 349 355
37. J. Back Activated human platelets induce factor XIIa-mediated contact activation Biochem. Biophys. Res. Commun. 391 2010 11 17
38. J. Johne Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma Biol. Chem. 387 2006 173 178
39. P.N. Walsh, and J.H. Griffin Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI Blood 57 1981 106 118
40. J.G. Latour Activation of Hageman factor by cardiac arrest Thromb. Diath. Haemor. 27 1972 543 553
41. P.N. Walsh The role of platelets in the contact phase of blood coagulation Br. J. Haematol. 22 1972 237 254
42. P.A. Castaldi Availability of platelet Factor 3 and activation of factor XII in thrombasthenia Nature 207 1965 422 424
43. C. Kannemeier Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation Proc. Natl. Acad. Sci. U. S. A. 104 2007 6388 6393
44. T.A. Fuchs Neutrophil extracellular trap (NET) impact on deep vein thrombosis Arterioscler. Thromb. Vasc. Biol. 32 2012 1777 1783
45. M.L. von Bruhl Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo J. Exp. Med. 209 2012 819 835
46. F.A. Ruiz Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes J. Biol. Chem. 279 2004 44250 44257
47. S.A. Smith Polyphosphate modulates blood coagulation and fibrinolysis Proc. Natl. Acad. Sci. U. S. A. 103 2006 903 908
48. S.A. Smith Polyphosphate exerts differential effects on blood clotting, depending on polymer size Blood 116 2010 4353 4359
49. S.A. Smith Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation Blood 120 2012 5103 5110
50. F. Muller Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo Cell 139 2009 1143 1156
51. F. Semeraro Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4 Blood 118 2011 1952 1961
52. C. Puy Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates J. Thromb. Haemost. 11 2013 1341 1352
53. K.F. Nickel Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation Blood 122 2013 3847 3849
54. P.H. Alvarenga Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate Arterioscler. Thromb. Vasc. Biol. 33 2013 2759 2770
55. S. Ghosh Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels Blood 122 2013 1478 1486
56. S.H. Choi Polyphosphate is a cofactor for the activation of factor XI by thrombin Blood 118 2011 6963 6970
57. M. Montilla Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with glycoprotein Ib J. Thromb. Haemost. 10 2012 2315 2323
58. N.J. Mutch Polyphosphate binds with high affinity to exosite II of thrombin J. Thromb. Haemost. 8 2010 548 555
59. J.M. Wat Polyphosphate suppresses complement via the terminal pathway Blood 123 2014 768 776
60. C. Maas The plasma contact system 2.0 Semin. Thromb. Hemost. 37 2011 375 381
61. J.W. Yau Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo Blood 118 2011 6667 6674
62. R.D. Frank Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride J. Mater. Sci. Mater. Med. 24 2013 2561 2566
63. M. Svensson Activation of FXII during haemodialysis Scand. J. Clin. Lab. Invest. 56 1996 649 652
64. A.A. Alturfan Investigation of inflammatory and hemostatic parameters in female patients undergoing total knee arthroplasty surgery Inflammation 31 2008 414 421
65. M. Cugno Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion Chest 120 2001 1776 1782
66. Y.T. Wachtfogel Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass Blood 73 1989 468 471
67. R. de Vroege The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass Artif. Organs 29 2005 490 497
68. M. Larsson A Factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk Sci. Translat. Med. 6 222 2014 ra217
69. A.H. Schmaier Extracorporeal circulation without bleeding Sci. Translat. Med. 6 222 2014 fs227
70. A. Matafonov Factor XII inhibition reduces thrombus formation in a primate thrombosis model Blood 123 2014 1739 1746
71. R.A. Pixley The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons J. Clin. Invest. 91 1993 61 68
72. R.A. Pixley A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalysed activation J. Biol. Chem. 262 1987 10140 10145
73. M.P. Esnouf A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor Thromb. Haemost. 83 2000 874 881
74. H. Saito Production and characterization of a murine monoclonal antibody against a heavy chain of Hageman factor (factor XII) Blood 65 1985 1263 1268
75. E.J. Small A monoclonal antibody that inhibits activation of human Hageman factor (factor XII) Blood 65 1985 202 210
76. Y. Hojima Hageman factor fragment inhibitor in corn seeds: purification and characterization Thromb. Res. 20 1980 149 162
77. J.W. Yau Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo Acta Biomater. 8 2012 4092 4100
78. N. Rajapakse A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation Life Sci. 76 2005 2607 2619
79. I. Hagedorn Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding Circulation 121 2010 1510 1517
80. Y. Xu Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit Thromb. Haemost. 111 2013 694 704
81. J.W. Chen Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway JACC Cardiovasc. Imaging 5 2012 1127 1138
82. Y. Ishimaru Dimiconin, a novel coagulation inhibitor from the kissing bug, Triatoma dimidiata, a vector of Chagas disease.J Exp. Biol. 215 2012 3597 3602
83. A.E. Davis 3rd C1 inhibitor, a multi-functional serine protease inhibitor Thromb. Haemost. 104 2010 886 893
84. Y. Decrem Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis J. Exp. Med. 206 2009 2381 2395
85. P. Kraft COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke Exp. Translat. Stroke Med. 2 2010 5
86. V. Baeriswyl Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy J. Med. Chem. 56 2013 3742 3746
87. R.S. Woodruff Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer J. Thromb. Haemost. 11 2013 1364 1373
88. A.S. Revenko Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding Blood 118 2011 5302 5311